BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9893058)

  • 1. C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.
    Chen CH; Lam CF; Boackle RJ
    Immunology; 1998 Dec; 95(4):648-54. PubMed ID: 9893058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses.
    Chen CH; Boackle RJ
    Clin Immunol Immunopathol; 1998 Apr; 87(1):68-74. PubMed ID: 9576012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component.
    Boackle RJ; Connor MH; Vesely J
    Mol Immunol; 1993 Feb; 30(3):309-19. PubMed ID: 8433709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the "arms" of C1q.
    Hoekzema R; Martens M; Brouwer MC; Hack CE
    Mol Immunol; 1988 May; 25(5):485-94. PubMed ID: 3261834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of C1q by monoclonal antibodies.
    Heinz HP; Loos M
    Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva.
    Su H; Boackle RJ
    Mol Immunol; 1991 Aug; 28(8):811-7. PubMed ID: 1875953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
    Hwang HY; Duvall MR; Tomlinson S; Boackle RJ
    Mol Immunol; 2008 May; 45(9):2570-80. PubMed ID: 18313756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
    van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
    J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
    Heinz HP; Burger R; Golan MD; Loos M
    J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the interactions between C-reactive protein and complement proteins.
    Bíró A; Rovó Z; Papp D; Cervenak L; Varga L; Füst G; Thielens NM; Arlaud GJ; Prohászka Z
    Immunology; 2007 May; 121(1):40-50. PubMed ID: 17244159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rat polymeric IgA binds C1q, but does not activate C1.
    Hiemstra PS; Rits M; Gorter A; Stuurman ME; Hoekzema R; Bazin H; Vaerman JP; van Es LA; Daha MR
    Mol Immunol; 1990 Sep; 27(9):867-74. PubMed ID: 2215479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved method for measuring C1-r-C1-s-(C1 inh)2 complexes by an enzyme-linked immunosorbent assay.
    Mathews KP; Herschbach JH; Chambers SL; Zuraw BL
    J Clin Lab Anal; 1995; 9(3):196-203. PubMed ID: 7602428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of C1 by monoclonal antibodies directed against C1q.
    Kilchherr E; Schumaker VN; Curtiss LK
    Biochem Biophys Res Commun; 1985 Jan; 126(2):785-91. PubMed ID: 3872122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
    Windfuhr JP; Alsenz J; Loos M
    Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
    Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
    Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
    Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
    J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
    Bindon CI; Hale G; Brüggemann M; Waldmann H
    J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.